acetylcarnitine has been researched along with Sensitivity and Specificity in 12 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated whether sodium bicarbonate-induced metabolic alkalosis could positively affect force development during the rest-to-work transition in ischaemic skeletal muscle." | 3.71 | Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle. ( Constantin-Teodosiu, D; Greenhaff, PL; Loxham, SJ; Poucher, SM; Roberts, PA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H | 1 |
| Wang, Y | 1 |
| Ma, S | 1 |
| Zhang, C | 1 |
| Liu, H | 1 |
| Sun, D | 1 |
| Magiera, S | 1 |
| Baranowska, I | 1 |
| Kusa, J | 1 |
| Baranowski, J | 1 |
| Hershman, DL | 1 |
| Unger, JM | 1 |
| Crew, KD | 1 |
| Minasian, LM | 1 |
| Awad, D | 1 |
| Moinpour, CM | 1 |
| Hansen, L | 1 |
| Lew, DL | 1 |
| Greenlee, H | 1 |
| Fehrenbacher, L | 1 |
| Wade, JL | 1 |
| Wong, SF | 1 |
| Hortobagyi, GN | 1 |
| Meyskens, FL | 1 |
| Albain, KS | 1 |
| Ladep, NG | 1 |
| Dona, AC | 1 |
| Lewis, MR | 1 |
| Crossey, MM | 1 |
| Lemoine, M | 1 |
| Okeke, E | 1 |
| Shimakawa, Y | 1 |
| Duguru, M | 1 |
| Njai, HF | 1 |
| Fye, HK | 1 |
| Taal, M | 1 |
| Chetwood, J | 1 |
| Kasstan, B | 1 |
| Khan, SA | 1 |
| Garside, DA | 1 |
| Wijeyesekera, A | 1 |
| Thillainayagam, AV | 1 |
| Banwat, E | 1 |
| Thursz, MR | 1 |
| Nicholson, JK | 1 |
| Njie, R | 1 |
| Holmes, E | 1 |
| Taylor-Robinson, SD | 1 |
| Xu, S | 1 |
| Waddell, J | 1 |
| Zhu, W | 1 |
| Shi, D | 1 |
| Marshall, AD | 1 |
| McKenna, MC | 1 |
| Gullapalli, RP | 1 |
| Lindeboom, L | 1 |
| Bruls, YM | 1 |
| van Ewijk, PA | 1 |
| Hesselink, MK | 1 |
| Wildberger, JE | 1 |
| Schrauwen, P | 1 |
| Schrauwen-Hinderling, VB | 1 |
| Ruggenenti, P | 1 |
| van der Meer, IM | 1 |
| Remuzzi, G | 1 |
| Roberts, PA | 1 |
| Loxham, SJ | 1 |
| Poucher, SM | 1 |
| Constantin-Teodosiu, D | 1 |
| Greenhaff, PL | 1 |
| Rashed, MS | 1 |
| Ozand, PT | 1 |
| Bucknall, MP | 1 |
| Little, D | 1 |
| Kamimori, H | 1 |
| Hamashima, Y | 1 |
| Konishi, M | 1 |
| Minkler, PE | 1 |
| Brass, EP | 1 |
| Hiatt, WR | 1 |
| Ingalls, ST | 1 |
| Hoppel, CL | 1 |
| Longo, A | 1 |
| Bruno, G | 1 |
| Curti, S | 1 |
| Mancinelli, A | 1 |
| Miotto, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy： A Randomized, Controlled, Open-label, Phase 2 Trail[NCT05601479] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-11-01 | Not yet recruiting | ||
| S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III[NCT00775645] | Phase 3 | 437 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compare fatigue outcome between treatment and placebo groups as measured by the 13-item Functional Assessment of Chronic Illness Therapy FACIT-fatigue questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate more fatigue. Total possible range is 0 to 52. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | FACIT-fatigue score (Mean) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 36.6 |
| Arm II (Placebo) | 35.3 |
Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity (NTX) component of the Functional Assesment of Cancer Therapy (FACT)-Taxane Questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse CIPN. Total possible range is 0 to 64. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 35.4 |
| Arm II (Placebo) | 36.3 |
Compare FACT-TOI outcome in treatment vs placebo groups at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse functional status. Total possible range is 0 to 120. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 92.1 |
| Arm II (Placebo) | 92.3 |
Proportion of patients experiencing grade 3 or 4 neuropathy (NCT00775645)
Timeframe: 12 weeks post-registration
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Acetyl-L-carnitine Hydrochloride)) | 8 |
| Arm II (Placebo) | 1 |
1 trial available for acetylcarnitine and Sensitivity and Specificity
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re | 2013 |
11 other studies available for acetylcarnitine and Sensitivity and Specificity
| Article | Year |
|---|---|
Clinical significance of small molecule metabolites in the blood of patients with different types of liver injury.
Topics: Acetylcarnitine; Adult; Biomarkers; Case-Control Studies; Female; Glycocholic Acid; Hepatitis B, Chr | 2021 |
A liquid chromatography and tandem mass spectrometry method for the determination of potential biomarkers of cardiovascular disease.
Topics: Acetylcarnitine; Biomarkers; Carnitine; Case-Control Studies; Chromatography, High Pressure Liquid; | 2013 |
Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans.
Topics: Acetylcarnitine; Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; alpha-Fetoproteins; Bi | 2014 |
In vivo longitudinal proton magnetic resonance spectroscopy on neonatal hypoxic-ischemic rat brain injury: Neuroprotective effects of acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Creatine; Drug Monitoring; Female; Humans; Hypoxia-Ischemia, Brain; Infant | 2015 |
Longitudinal relaxation time editing for acetylcarnitine detection with
Topics: Acetylcarnitine; Adult; Aged; Algorithms; Female; Humans; Lipids; Magnetic Resonance Imaging; Male; | 2017 |
Oral acetyl-L-carnitine therapy and insulin resistance.
Topics: Acetylcarnitine; Administration, Oral; Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mel | 2010 |
Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle.
Topics: Acetylcarnitine; Alkalosis; Animals; Carnitine; Dogs; Electric Stimulation; Female; Infusions, Intra | 2002 |
Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry.
Topics: Acetylcarnitine; Amino Acids; Automation; Blood Chemical Analysis; Humans; Infant, Newborn; Mass Spe | 1995 |
Determination of carnitine and saturated-acyl group carnitines in human urine by high-performance liquid chromatography with fluorescence detection.
Topics: Acetylation; Acetylcarnitine; Calibration; Carnitine; Chromatography, High Pressure Liquid; Chromato | 1994 |
Quantification of carnitine, acetylcarnitine, and total carnitine in tissues by high-performance liquid chromatography: the effect of exercise on carnitine homeostasis in man.
Topics: Acetophenones; Acetylcarnitine; Carnitine; Chromatography, High Pressure Liquid; Exercise; Homeostas | 1995 |
Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene.
Topics: Acetylcarnitine; Anthracenes; Carnitine; Chromatography, High Pressure Liquid; Fluorescent Dyes; Hum | 1996 |